Product Description.:
Drops , clear , clear
* Convenient one-drop formulation is easier to administer than many current regimens consisting of a drop from two separate products.
For Patient and Practitioner Convenience
* Formulated to work quickly to fit busy patients' schedules and your patient flow.
* Only partial loss of accommodation, due to lower (0.25%) concentration of tropicamide.
* Minimizes inconvenience: Recovery begins within 90 minutes, with complete recovery typically in 6 to 8 hours.
PAREMYD? Solution should not be used in patients with angle-closure glaucoma or in those with narrow angles in whom dilation of the pupil may precipitate an attack of angle-closure glaucoma. This product is also contraindicated in patients who are hypersensitive to any of its components.
DRUG DESCRIPTION
PAREMYD? sterile ophthalmic solution is a topical mydriatic combination product for ophthalmic use.
INDICATIONS
PAREMYD? Solution is indicated for mydriasis in routine diagnostic procedures and in conditions where short-term pupil dilation is desired. PAREMYD? provides clinically significant mydriasis with partial cycloplegia.
DOSAGE AND ADMINISTRATION
One to two drops in the conjunctival sac. The onset of action with PAREMYD? Solution occurs within 15 minutes followed by maximum effect within 60 minutes. Clinically significant dilation, inhibition of pupillary light response, and partial cycloplegia last 3 hours. Mydriasis will reverse spontaneously with time, typically in 6 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.
SIDE EFFECTS
Increased intraocular pressure has been reported following use of mydriatics. Transient stinging, dryness of the mouth, blurred vision, photophobia with or without corneal staining, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, and muscle rigidity have been reported with the use of tropicamide and/or hydroxyamphetamine hydrobromide, and thus may occur with PAREMYD? Solution. Central nervous system disturbances have also been reported. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse have been reported with the use of anticholinergic drugs. Rare but serious cardiovascular events, including death due to myocardialinfarction, ventricular fibrillation and significant hypotensive episodes have occurred shortly following PAREMYD? instillation.
